Analysis
The full analysis set included all randomized patients who received at least one dose of the study drug during PODs 1–5. It excluded those without baseline data or major protocol violations (e.g., absence of informed consent). If missing data were identified, the investigator contacted the patient to resolve missing values. If the within‐subject difference or ΔVAS could not be determined due to missing VAS scores, it was considered as 0. If data other than VAS scores were missing or incomplete, the analysis could not be performed.Continuous data were tabulated and summarized using the mean, SD, and 95% confidence intervals (CIs). In addition, categorical data were summarized using counts and percentages. For primary analysis, within‐subject difference for treatment, carryover, and period effects was estimated based on ΔVASThe full analysis set was used for the primary analysis of this study. Sub‐analyses were also performed to address any imbalances in patient background, considering the effect of covariates. All analyses were performed using R (R Core Team, 2022, version 4.2.0).